Skip to main content
. 2022 Sep 20;11(19):5494. doi: 10.3390/jcm11195494

Table 1.

Characteristics of the subjects (epinephrine injected group vs. non-injected group) (n = 107).

Epinephrine Injected (n = 76) Epinephrine not Injected (n = 31) Total (n = 107) p-Value
n % n % n %
Sex (boy, n,%) 42 55.30% 21 67.70% 63 58.90% 0.234
Age (median, yr) † 3.5 (1.0–7.75) 5.0 (3.0–10.0) 4.0 (1.0–8.0)
Age group 0.212
<2 yr 24 31.60% 5 16.10% 29 27.10%
≥2, <6 yr 26 34.20% 11 35.50% 37 34.60%
≥6 yr 26 34.20% 15 48.40% 41 38.30%
All allergic histories 57 75% 20 64.5 77 72% 0.273
Anaphylaxis 8 10.5 2 6.5 10 9.3 0.511
Bronchial asthma 16 21.1 3 9.7 19 17.8 0.162
Drug allergy 4 5.3 1 3.2 5 4.7 0.651
Food allergy 31 40.8 11 35.5 42 39.3 0.610
Allergic rhinitis 21 27.6 6 19.4 27 25.2 0.371
Atopic dermatitis 27 35.5 7 22.6 34 31.8 0.192
Familial allergy history 26 34.2 10 32.3 36 33.6 0.846
Arrival time to hospital (median, min) † 50.0 (29.25–104.75) (n = 76) 94 (42.5–146.5), (n = 29) <0.001 *
Eosinophil (median, %) 1.0 (0.6–2.1), (n = 55) 1.0 (0.65–3.65), (n = 21) 1.0 (0.625–2.25), (n = 76) 0.378
Total IgE (U/mL) 146 (42.5–420.5), (n = 54) 121 (62.5–304.0), (n = 21) 132.9 (47.9–380), (n = 75) 0.648

* indicates a p-value of < 0.05, and † indicates the interquartile range.